research

Health-related quality of life in KEYNOTE-010 : a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC (vol 14, pg 793, 2019)

Authors
Publication date
1 January 2019
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Ghent University Academic Bibliography

    redirect
    oaioai:archive.ugent.be:8646324
    Last time updated on 18/03/2020